Wall Street Upgrades Rezolute After Strong Phase 3 Trial Results in Tumor Hyperinsulinism
Rezolute’s drug showed strong Phase 3 results, reducing IV glucose needs in rare tumor HI. Analysts raised targets and turned bullish.
/ 2 items
Rezolute’s drug showed strong Phase 3 results, reducing IV glucose needs in rare tumor HI. Analysts raised targets and turned bullish.
Rezolute's ersodetug therapy for congenital hyperinsulinism failed Phase 3 trial, missing primary endpoints. Stock plunged 90% as the drug showed no significant advantage over placebo.